AMA resolution calls for ad moratorium

Share this article:
The American Medical Association will advocate a mandatory moratorium on consumer advertising for new drugs.

At an AMA house of delegates meeting in Chicago last month, the group's membership passed a resolution recommending that the FDA adopt a moratorium on ads for new drugs. However, the organization did not specify a time-frame for the ad ban, instead suggesting that the FDA use its discretion based on the available scientific evidence for a drug's safety and efficacy.

“A temporary moratorium on DTC advertising of prescribed drugs and medical devices will benefit both the patient and the physician,” said AMA president-elect Ronald Davis, M.D.

The AMA's recommendation largely parallels existing PhRMA guidelines on DTC, which call for companies to “spend an appropriate amount of time to educate health professionals about a new medicine or a new therapeutic indication before commencing the first DTC advertising campaign,” but leave the interim up to the manufacturer, asserting that flexibility is necessary to allow for the urgency with which a new drug may be needed.

“AMA's vision of a DTC moratorium looks like government censorship, not patient empowerment, free speech or enlightened public policy,” said John Kamp, executive director of the Coalition for Healthcare Communications. “PhRMA's DTC Principles put the decision to advertise where it belongs, in the hands of the companies that know the most about their drugs and the information needs of doctors and patients.”

The AMA also called for all drug ads to be pre-approved by the FDA and for equal space to be allotted to risks and benefits in advertising.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.